Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Pfizer Inc. announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Pfizer's complaint is that GSK and a Quebec, Canada-based subsidiary ID Biomedical are causing "commercial uncertainty" for its own RSV vaccine programme with the three patents, which Pfizer says ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

In October 2024, Pfizer received FDA approval for the first RSV vaccine for adults younger than age 50. Yes. Pfizer has paid dividends to its shareholders for 345 consecutive quarters as of the ...

Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

Sanofi SNY reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, which beat the Zacks Consensus Estimate of 90 cents per share. Earnings of €1.79 per share rose 17.0 ...